Imfinzi combo backed for NHS use in biliary tract cancer

23 November 2023

Imfinzi (durvalumab), in combination with gemcitabine and cisplatin (chemotherapy), has been recommended for National Health Service (NHS) use in England and Wales for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC) by the National Institute for Health and Care Excellence (NICE).

Already approved in other cancer indications, Imfinzi is one UK pharma major AstraZeneca’s (LSE: AZN) best selling drugs, generating global sales of $2.8 billion last year.

AstraZeneca noted that there remains a significant unmet need for new treatment options in BTC, a group of rare and aggressive cancers that occur in the bile ducts and gallbladder, with only around 5%-15% of patients surviving five years. Worldwide, bile duct cancer, or biliary tract cancer as it is most commonly known, is the second most common primary liver cancer with incidence rates increasing in many western countries, including the UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK